Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release

About Insmed

Insmed is a biopharmaceutical company focused on the discovery anddevelopment of drug candidates for the treatment of metabolic diseasesand endocrine disorders. For more information, please visitwww.insmed.com.

Statements included within this press release, which are nothistorical in nature, may constitute forward-looking statements forpurposes of the safe harbor provided by the Private SecuritiesLitigation Reform Act of 1995. Forward-looking statements in thispress release include, but are not limited to, statements regardingclinical trials and goals, our regulatory and business strategies andgrowth opportunities for existing or proposed products. Suchforward-looking statements are subject to numerous risks anduncertainties, including risks that product candidates may fail in theclinic or may not be successfully marketed or manufactured, thecompany may lack financial resources to complete development ofproduct candidates, the FDA may interpret the results of our studiesdifferently than we have, competing products may be more successful,demand for new pharmaceutical products may decrease, thebiopharmaceutical industry may experience negative market trends andother risks detailed from time to time in the company's filings withthe Securities and Exchange Commission. As a result of these and otherrisks and uncertainties, actual results may differ materially fromthose described in this press release. For further information withrespect to factors that could cause actual results to differ fromexpectations, reference is made to reports filed by the Company withthe Securities and Exchange Commission under the Securities ExchangeAct of 1934, as amended. The forward-looking statements made in thisrelease are made only as of the date hereof and Insmed disclaims anyintention or responsibility for updating predictions or financialguidance contained in this release.